Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes)

Human Gene Therapy

Volumn 10, Issue 17, 1999, Pages 2847-2857

  Wu, Yaping ^a   Yu, Lijuan ^a   McMahon, Ross ^a   Rossi, John J ^a   Forman, Stephen J ^a   Snyder, David S ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; RIBOZYME;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; GENE EXPRESSION; GENE INACTIVATION; GENE LOCATION; GENE TARGETING; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN RNA BINDING;

ALTERNATIVE SPLICING; ANTIGENS, CD34; CELL-FREE SYSTEM; DNA, CATALYTIC; DNA, SINGLE-STRANDED; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; GENE TARGETING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC; LIPOSOMES; NUCLEIC ACID CONFORMATION; RNA, MESSENGER; SUBSTRATE SPECIFICITY; TRANSFECTION; TRANSPLANTATION, AUTOLOGOUS;

EID: 0033589752     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950016573     Document Type: Article

References (32)

1. AMARANTE-MENDES, G.P., JASCUR, T., NISHIOKA, W.K., MUSTELIN, T., and GREEN, D.R. (1997). Bcr-Abl-mediated resistance to apoptosis is independent of PI 3-kinase activity. Cell Death Differ. 4, 548-554.
2. BEDI, A., ZEHNBAUER, B.A., BARBER, J.P., SHARKIS, S.J., and JONES, R.J. (1994). Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83, 2038-2044.
3. BUTTURINI, A., ARLINGHAUS, R.B., and GALE, R.P. (1996). BCR/ABL and leukemia. Leuk. Res. 20, 523-529.
4. GAMBIER, N., CHOPRA, R., STRASSER, A., METCALF, D., and ELEFANTY, A.G. (1998). BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene 16, 335-348.
5. CAMPBELL, M.L., and ARLINGHAUS, R.B. (1991). Current status of the BCR gene and its involvement with human leukemia. Adv. Cancer Res. 57, 227-256.
6. CHASTY, R., WHETTON, A., and LUCAS, G. (1996). A comparison of the effect of bcr/abl breakpoint specific phosphothiorate oligodeoxynucleotides on colony formation by bcr/abl positive and negative. CD34 enriched mononuclear cell populations. Leuk. Res. 20, 391-395.
7. DALEY, G.Q., and BEN-NERIAH, Y. (1991). Implicating the bcr/abl gene in the pathogenesis of Philadelphia chromosome-positive human leukemia. Adv. Cancer Res. 57, 151-184.
8. DE FABRITIIS, P., PETTI, M.C., MONTEFUSCO, E., DE PROPRIS, M.S., SALA, R., BELLUCCI, R., MANCINI, M., LISCI, A., BONETTO, F., GEISER, T., CALABRETTA, B., and MANDELLI, F. (1998). BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood 91, 3156-3162.
9. DOBROVIC, A., TRAINOR, K.J., and MORLEY, A.A. (1988). Detection of the molecular abnormality in chronic myeloid leukemia by use of the polymerase chain reaction. Blood 72, 2063-2065.
10. DUBREZ, L., EYMIN, B., SORDET, O., DROIN, N., TURHAN, A.G., and SOLARY, E. (1998). BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood 91, 2415-2422.
11. GILES, R.V., SPILLER, D.G., GREEN, J.A., CLARK, R.E., and TIDD, D.M. (1995). Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA. Blood 86, 744-754.
12. GROFFEN, J., STEPHENSON, J.R., HEISTERKAMP, N., DE KLEIN, A., BARTRAM, C.R., and GROSVELD, G. (1984). Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36, 93-99.
13. HEISTERKAMP, N., JENSTER, G., TEN HOEVE, J., ZOVICH, D., PATTENGALE, P.K., and GROFFEN, J. (1990). Acute leukaemia in bcr/abl transgenic mice. Nature (London) 344, 251-253.
14. HENDRY, P., McCALL, M.J., SANTIAGO, F.S., and JENNINGS, P.A. (1992). A ribozyme with DNA in the hybridising arms displays enhanced cleavage ability. Nucleic Acids Res. 20, 5737-5741.
15. HONMA, Y., MATSUO, Y., HAYASHI, Y., and OMURA, S. (1995). Treatment of Philadelphia-chromosome-positive human leukemia in SCID mouse model with herbimycin A, bcr-abl tyrosine kinase activity inhibitor. Int. J. Cancer 60, 685-688.
16. KEARNEY, P., WRIGHT, L.A., MILLIKEN, S., and BIGGS, J.C. (1995). Improved specificity of ribozyme-mediated cleavage of bcr-abl mRNA. Exp. Hematol. 23, 986-989.
17. KUWABARA, T., WARASHINA, M., TANABE, T., TANI, K., ASANO, S., and TAIRA, K. (1997). Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA. Nucleic Acids Res. 25, 3074-3081.
18. LANGE, W., SNYDER, D.S., CASTRO, R., ROSSI, J.J., and BLUME, K. (1989). Detection by enzymatic amplification of bcr-abl mRNA in peripheral blood and bone marrow cells of patients with chronic myelogenous leukemia. Blood 73, 1735-1741.
19. LANGE, W., CANTIN, E.M., FINKE, J., and DOLKEN, G. (1993). In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA. Leukemia 7, 1786-1794.
20. LEWIS, J.G., LIN, K.Y., KOTHAVALE, A., FLANAGAN, W.M., MATTEUCCI, M.D., DEPRINCE, R.B., MOOK, R.A., JR., HENDREN, R.W., and WAGNER, R.W. (1996). A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc. Natl. Acad. Sci. U.S.A. 93, 3176-3181.
21. McLAUGHLIN, J., CHIANESE, E., and WITTE, O.N. (1987). In vitro transformation of immature hematopoietic cells by the p210 bcr/abl oncogene product of the Philadelphia chromosome. Proc. Natl. Acad. Sci. U.S.A. 84, 6558-6562.
22. SÁNCHEZ-GARCÍA, I., and GRÜTZ, G. (1995). Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc. Natl. Acad. Sci. U.S.A. 92, 5287-5291.
23. SANTORO, S.W., and JOYCE, G.F. (1997). A general purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. U.S.A. 94, 4262-4266.
24. SMETSERS, T.F.C.M., SKORSKI, T., VAN DE LOCHT, L.T.F., WESSELS, H.M.C., PENNINGS, A.H.M., DE WITTE, T., CALABRETTA, B., and MENSINK, E.J.B.M. (1994). Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia 8, 129-140.
25. SMETSERS, T.F.C.M., and MENSINK, E.J.B.M. (1995). Specificity of BCR-ABL antisense oligonucleotides. Blood 85, 597-598.
26. SNYDER, D.S., and McGLAVE, P.B. (1990). Treatment of chronic myelogenous leukemia with bone marrow transplantation. In Hematology/Oncology Clinics of North America Bone Marrow Transplantation, Vol. 4, No. 3. S.J. Forman, ed. (W.B. Saunders, Philadelphia) pp. 535-558.
27. SNYDER, D.S., WU, Y., WANG, J.L., ROSSI, J.J., SWIDERSKI, P., KAPLAN, B.E., and FORMAN, S.J. (1993). Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood 82, 600-605.
28. SNYDER, D.S., WU, Y., McMAHON, R., YU, L., ROSSI, J.J., and FORMAN, S.J. (1997). Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p 190 bcr-abl oncogene. Biol. Blood Marrow Transplant. 3, 179-186.
29. SZCZYLIK, C., SKORSKI, T., NICOLAIDES, N.C., MANZELLA, L., MALAGUARNERA, L., VENTURELLI, D., GEWIRTZ, A.M., and CALABRETTA, B. (1991). Selective inhibition of leukemia cell proliferation by bcr-abl antisense oligodeoxynucleotides. Science 253, 562-565.
30. TABLER, M., HOMANN, M., TZORTZAKAKI, S., and SCZAKIEL, G. (1994). A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: Advantages of an asymmetric design. Nucleic Acids Res. 22, 3958-3965.
31. VAERMAN, J.L., LAMMINEUR, C., MOUREAU, P., LEWALLE, P., DELDIME, F., and BLUMENFELD, M. (1995). BCR-ABL anti-sense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. Blood 86, 3891-3896.
32. WALKER, L.C., GANESAN, T.S., DHUT, S., GIBBONS, B., LISTER, T.A., ROTHBARD, J., and YOUNG, B.D. (1987). Novel chimaeric protein expressed in Philadelphia positive acute lymphoblastic leukaemia. Nature (London) 329, 851-853.